What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it?

Schizophrenia Bulletin
Aaron S KempAn Vermeulen

Abstract

On September 18, 2007, a collaborative session between the International Society for CNS Clinical Trials and Methodology and the International Society for CNS Drug Development was held in Brussels, Belgium. Both groups, with membership from industry, academia, and governmental and nongovernmental agencies, have been formed to address scientific, clinical, regulatory, and methodological challenges in the development of central nervous system therapeutic agents. The focus of this joint session was the apparent diminution of drug-placebo differences in recent multicenter trials of antipsychotic medications for schizophrenia. To characterize the nature of the problem, some presenters reported data from several recent trials that indicated higher rates of placebo response and lower rates of drug response (even to previously established, comparator drugs), when compared with earlier trials. As a means to identify the possible causes of the problem, discussions covered a range of methodological factors such as participant characteristics, trial designs, site characteristics, clinical setting (inpatient vs outpatient), inclusion/exclusion criteria, and diagnostic specificity. Finally, possible solutions were discussed, such as improvin...Continue Reading

References

Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Oct 1, 1995·Archives of General Psychiatry·A C LeonL Portera
Dec 6, 2000·Journal of Clinical Psychopharmacology·A HoferW W Fleischhacker
Jan 5, 2002·Journal of Clinical Psychopharmacology·D E FariesW Z Potter
Apr 23, 2003·Biological Psychiatry·Craig H MallinckrodtGary D Tollefson
Nov 19, 2004·European Archives of Psychiatry and Clinical Neuroscience·M RiedelH-J Möller
Feb 21, 2006·NeuroRx : the Journal of the American Society for Experimental NeuroTherapeutics·Orest Hurko, John L Ryan
Sep 11, 2007·Journal of Psychiatric Research·Kenneth S LiuWilliam Z Potter
Feb 1, 2008·Schizophrenia Bulletin·Stefan LeuchtJohn M Kane

❮ Previous
Next ❯

Citations

May 14, 2009·Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz·P EnckS Klosterhalfen
Dec 10, 2013·Lancet·Cynthia O SiuGary Remington
Jul 19, 2013·Translational Psychiatry·D BorsookM Fava
Dec 14, 2012·Drug, Healthcare and Patient Safety·Arão Nogueira de AraújoMario F Juruena
Jun 12, 2013·Biochemical Pharmacology·Michael J Marino
Feb 5, 2014·Schizophrenia Bulletin·Stefan LeuchtJohn M Davis
Jan 10, 2013·Annual Review of Clinical Psychology·Melissa FisherSophia Vinogradov
Aug 25, 2012·The British Journal of Psychiatry : the Journal of Mental Science·Mauricio TohenJuan-Carlos Gomez
Jan 15, 2013·Psychopharmacology·Hsun-Hua ChouNeal R Swerdlow
Jan 15, 2013·Journal of Pharmacokinetics and Pharmacodynamics·Venkatesh Pilla ReddyJohannes H Proost
Nov 13, 2012·The Psychiatric Quarterly·J C HoblynUNKNOWN CSP 555 Investigator Group
Dec 30, 2011·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Eduara Vieta, Nuria Cruz
Apr 2, 2011·Journal of Psychiatric Research·Craig H MallinckrodtYoko Tanaka
Jan 1, 2011·Revista de psiquiatrí́a y salud mental·Ross J Baldessarini
Mar 2, 2016·Drugs·Jean-Pierre Lindenmayer, Amandeep Kaur
Feb 13, 2013·Alcoholism, Clinical and Experimental Research·A C Del ReJohn Finney
Sep 29, 2011·Alcoholism, Clinical and Experimental Research·Raye Z LittenUNKNOWN NCIG 001 Study Group
Feb 13, 2013·Annals of the New York Academy of Sciences·Carlo ContoreggiGeorge Chrousos
Jul 31, 2013·Alcoholism, Clinical and Experimental Research·Raye Z LittenHsiao-ye Yi
Aug 8, 2013·British Journal of Clinical Pharmacology·Taro KunitomiMayumi Mochizuki
Jul 1, 2015·Evidence-based Mental Health·Markus Dold, Siegfried Kasper
Jul 22, 2015·Nature Reviews. Gastroenterology & Hepatology·Sigrid Elsenbruch, Paul Enck
Mar 31, 2015·The Lancet. Psychiatry·Katja WeimerPaul Enck
Apr 25, 2015·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·C C M WeltenD A J P Denys
Aug 30, 2011·Schizophrenia Research·Steven PotkinGary Remington
Oct 8, 2013·Schizophrenia Research·Robin Emsley, Wolfgang W Fleischhacker
Mar 29, 2011·The International Journal of Neuropsychopharmacology·Gustavo VázquezPaola Salvatore
Jan 6, 2012·The International Journal of Neuropsychopharmacology·Larry AlphsJohn M Kane
Sep 26, 2013·The International Journal of Neuropsychopharmacology·Brian DeanMark J Millan
Feb 9, 2011·The International Journal of Neuropsychopharmacology·Ayşegül YildizRoss J Baldessarini
Apr 24, 2016·Lancet Neurology·Fabrizio BenedettiAlessandro Piedimonte
Jul 26, 2016·Frontiers in Psychology·Efrat CzerniakAtay Citron

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here